CME: Metastatic cutaneous melanoma: Updates from the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
ACCREDITATION EXPIRED: January 29, 2026
Activity Description / Statement of Need:
In this online, self-learning activity:
Melanoma is a tumor of the melanocytes primarily occurring in the skin. The fifth most common cancer in the U.S., it occurs in over 100,000 people annually and is attributable to over 8,200 deaths each year. It is also one of the most common cancers in young adults. The five-year survival rate from diagnosis overall is 80% to 99% for patients with early stages of the disease, depending on tumor thickness. However, in patients in whom the disease that has spread to adjacent lymph nodes or tissues, the five-year survival drops to 71%, and for those with distant metastases (five percent of cases are diagnosed at this stage), the five-year survival is 32%, representing an area of ongoing clinical need.
Target Audience:
HCPs including: medical oncologists and dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with malignant melanoma.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: January 29, 2025 -- Expiration Date: January 29, 2026
Faculty: Allison Betof Warner, MD, PhD
Agenda
|
Faculty introduction, disclosures |
|
Introductory content and review of metastatic cutaneous melanoma
|
|
|
Summary and concluding remarks |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at the ESMO 2024 annual meeting relating to metastatic cutaneous melanoma (inclusive of disease diagnosis, progression, prognosis, evaluation of degree therapeutic success, quantifying benefit and risk of disease progression and therapeutic, and emerging therapies), and apply them to patient cases.
- Understand the magnitude of benefit of adjuvant therapy for stage IIB-IIC melanoma.
- Evaluate updated data in neoadjuvant therapy for advanced melanoma.
- Characterize long-term survival data for first-line immunotherapy for advanced melanoma.
- Analyze updated data for the oncolytic virus RP1 from the IGNYTE trial.
Accreditation
ACCME Activity #202895831
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Allison Betof Warner, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology, Stanford University School of Medicine, has received financial compensation from Adaptimmune, Bristol Myers Squibb, Immatics, IO Biotech Iovance Biotherapeutics, Lyell Immunopharma, Novartis, Merck, Pfizer, and Obsidian Therapeutics as a consultant; in addition to grant/research work from Bristol Myers Squibb, Iovance Biotherapeutics, Lyell Immunopharma.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
The state of prostate cancer treatment: advances in approach for advanced disease
Advanced systemic mastocytosis: from recognition to treatment